top of page

Pramana

Pramana

HARNESSING THE POWER OF GPCRS

A Novel Approach to Therapeutic Development for Immuno-Metabolic Disorders

Immuno-metabolism

We are driving drug development for a new mechanism of action powered by our novel small molecule platform.  We are committed to enable better treatment options for patients. 

About us

GPCR Centric

We are a GPCR centric advancing a broad pipeline of biologic drug candidates. Our large library of Novel potent and selective GPCR agonists was discovered and optimized in-house....by a team that has discovered many important drugs.

Pipeline 

Improving lives targeting GPCRs

Pramana’s Lead Compound, PRM A activates a differentiated immune response which could enable breakthrough treatments for multiple indications associated with metabolic dysregulation. 

The Market

Untapped Opportunity

The Team

Driving Success

Pramana has pioneered a revolutionary small molecule platform designed to combat cardiometabolic diseases. Our lead clinical candidate is progressing through multiple indications, supported by groundbreaking preclinical data. This innovative platform targets metabolic dysfunctions associated with Diabetes, Obesity, NASH, and Neurodegenerative diseases. Behind Pramana is a world-class scientific team, each member bringing extensive experience from leading global pharmaceutical companies. Collectively, they have invented and contributed to numerous significant drugs, improving the lives of millions of patients worldwide. 

Platform 

Diabetes, Obesity & Cardio Metabolic Disorders

Overseen by a world class scientific team, Pramana has utilized their expertise in the development of its highly potent, selective small molecules.

490,000,000,000

Dollars in Global Healthcare Expenditures of Diabetes by 2030

537,000,000

People currently live with diabetes

1,000,000,000+

People will suffer from diabetes by 2050

The unmet opportunity - Pramana's commitment

The opportunity for an Oral Preventative Treatment for Hypoglycemia is just one of many areas of high unmet medical need associated with Metabolic Disorders. We are committed to addressing this.

100,000,000

 

 

People living with Diabetes may be misdiagnosed and affected by Latent Autoimmune Diabetes in Adults right now

The opportunity to treat Latent Autoimmune Diabetes in adults is an area of high unmet medical need associated with Immunometabolic disorders. We are committed to addressing this.

bottom of page